🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Zai Lab Limited (HKG:9688)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
16.39
-0.96 (-5.53%)
Nov 20, 2026, 4:08 PM HKT
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

Zoci’s global push anchors a broader pipeline and planned 2028 launch.

Speaker 1

Everyone, thanks for joining Jefferies Conference. Today, we are very glad to have the CFO, Dr. Chen Yajing from Zai Lab, and also Dr. Rafael Amado, President and Head of Global Research of Zai Lab. Thank you so much. We all know that Zai Lab has experienced remarkable evolution from a China-focused in-licensing company and a commercial platform to a true global innovation-led biopharm. Maybe, Dr. Yajing, may I know what do you think are the most critical capabilities behind this evolution, and also, what do you think is the investors underappreciate about Zai today?

Yajing Chen
CFO, Zai Lab

Yeah, thank you for the question. It's a very good question. Zai Lab was founded with a vision to become a global leading innovative biopharma. We started by building a strong foundation in China, but our ambition has always been to discover and develop medicines for the patient in the world. I think as we speak now, we're closer than ever to our first potential BLA submission in 2027 and launch in 2028. To what has made it possible, I think in my mind, in maybe in three fronts. First of all, you need to have a very sound scientific judgment.

Over the years, we have evaluated hundreds of assets. We were able to choose the best one with the truly differentiated products with compelling science. This same guidance, I mean, principle, guides us through our internal discovery and development as well. I think that's the first one. Secondly, it's really about our strong R&D capability. Under Rafael, we have built a team that is fully capable of executing the global studies, and all the way through discovery to regulatory.

This commercial, I mean, this R&D team capability is crucial. The third, I think that stays with internally our execution with discipline. We really put and concentrate all the resources on the programs that has highest probability of changing practice, right? That focus made it possible that how we see program zoci and ZL-1503 are moving so efficiently right now. I don't know whether Rafael has anything to add on that piece, the R&D capability piece.

Rafael Amado
President and Head of Global Research and Development, Zai Lab

No, I echo what you said. I think the critical thing is to have access to molecules that are grounded on fundamental biology, making sure the molecules are differentiated, and then as you say, execution is critical. One has to have people that actually are discerning enough to be able to choose the right molecules, but also all along the end-to-end spectrum of drug development, build a team of people that actually know how to develop drugs across multiple jurisdictions.

That's not just simply execution of being able to put patients on trials, but making sure that the studies are tailored to what is going to move the needle in terms of this next standard of care for the disease, that we watch out for the right dose, that we take care of the making sure that safety is safeguarded for molecules that may have a narrower therapeutic index. So in essence, to have the expertise of having done this before and developed drugs globally for whatever therapeutic area we're working on.

Yajing Chen
CFO, Zai Lab

Yeah. I mean, to also answer the second part of your question in terms of when I look at the valuation of Zai Lab, I really think the market probably missing two things in my mind. On top of the regionally already profitable commercial business, we have a very strong global pipeline, which I want to emphasize. First of all, zoci, our zoci program is very, very close to become a true global product very soon. We also have a robust first-line strategy right now with multiple combinations, right? So this zoci is potentially their best class, sort of a DLL3 in the ADC space.

I think, with the first-line combinations in play and several small cell lung cancer plus neuroendocrine carcinoma, I think this position the zoci really well in a large opportunity market. I think second point is, maybe more important, the bigger picture, Zai right now is not a one single asset coming global asset company. Behind zoci, you have ZL-1503 coming in, and then that's in the atopic dermatitis, which is one of the largest market in immunology, right? Behind all those, we have a sort of a pipeline behind it. That pipeline is built from the same engine that we kind of pushing zoci and ZL-1503 forward. I think in the next 12- 18 months, you are going to see, we are going to show investors that Zai Lab is delivering an innovative pipeline of medicine.

Speaker 1

Yeah. Thank you, Yajing, and thank you, Rafael. Speaking of the transition, I think the zoci is the most vivid example of Zai Lab's transition. Maybe, Rafael, could you please share with us, how do you view zoci's opportunities in the first-line small cell lung cancer, and how do you think it will ultimately differentiate itself versus the other chemo-IO therapy combination? Thanks.

Rafael Amado
President and Head of Global Research and Development, Zai Lab

Yeah, maybe I'll answer the second one first. First, the target is unique in that it's not expressed in normal tissue, and for antibody-drug conjugates, the target expression is really important. That translates into safety, and this is a strong characteristic of this ADC. Zoci is probably the safest ADC that there is either on the market or in development. We've done a lot of very careful dose finding to make sure that we thread the needle well in terms of benefit-risk. Then it's highly effective. We tested that in second line and beyond in small cell lung cancer, and we saw responses in the high 60% that were durable.

And then importantly in this disease, small cell lung cancer brain metastasis is a big problem with patients developing it either de novo or during the disease, and that pertains a very poor prognosis, and zoci is very active in preventing and also treating brain metastasis. Our first phase III study started about two years after we acquired the molecule, and we acquired it prior to IND, so that goes to the ability to move products quickly. After that, well, that study is already ongoing. We have another study in neuroendocrine carcinomas in second line. But to answer your question in front line, the field is changing dramatically, particularly with the advent of IMDELLTRA.

You probably all heard about 305 in maintenance. So, we conducted a phase II study with IO plus zoci in patients that were previously untreated, and we were very pleased with the results in that 81% of patients responded. That contrasts with about 60%-70% of patients with chemotherapy. But also, the responses were very durable, and the progression-free survival, which is about five months with chemo-IO, was not reached after 10 months. The median survival in this disease has been about a year. So, our PFS was approaching the median survival of the disease with what it is, contemporary therapy, until maintenance really gets approved, maintenance IMDELLTRA.

So, to that end, we're going to launch a doublet study with zoci and IO against chemotherapy plus maintenance, lurbinectedin, and eventually IMDELLTRA when it gets approved. I think more exciting regimens will probably come from the combination of T-cell engagers with ADCs, because ADCs can induce brisk responses in patients with large tumor volumes, and then T-cell engagers can come in and attract T-cells to the tumor bed and cause even deeper responses that are longer-lasting, through either the cognate antigen, like DLL3, or other antigens that are expressed in the context of HLA.

So, that combination is really promising. We already announced a partnership with both Amgen and Boehringer Ingelheim to test the combination, and we hope that that can evolve into a phase III study. So, our strategy is to be the ADC that's the cornerstone, if you will, of the treatment of both neuroendocrine carcinomas as well as small cell lung cancer. We're starting in second line, and we're moving very quickly into first.

Speaker 1

Yeah, thank you. Zoci definitely got the most attention today. I think maybe nowadays, the bigger questions from the investors are what comes after the zoci? Rafael, may I know, as you are building the next generation of your pipeline, maybe also beyond the ADCs and the new modalities, how would you decide what to develop internally? How has the bar changed for sourcing external assets as your internal R&D capabilities has strongly strengthened?

Rafael Amado
President and Head of Global Research and Development, Zai Lab

Yeah, good question. I think zoci was being developed as we built these capabilities. It started again pre-IND. There was an enormous amount of work on bringing this molecule all the way to phase III, and also to have the people that could execute globally. Obviously, the execution in China is very good because that's been the tradition of the company, but we needed to be able to execute at all levels globally. That has given us the opportunity to bring more molecules in the two therapy areas where we are developing drugs. One is oncology and the other is immunology.

In oncology, we're focusing on antibody-drug conjugates and new generations of ADCs. We also are focusing on T-cell engagers as well as immunocytokines. We have a lot of expertise in protein engineering, and that is helping us particularly with the immunocytokines as well as the other two modalities. Then in immunology, we have ZL-1503, which we can talk about later on, in immunology for atopic dermatitis. It's essentially interdicting signaling of cytokines with their cognate receptors or blocking receptors of cytokines or chemokines, again, requiring a lot of protein engineering know-how, and then development capabilities globally. These molecules, some come from business development, but increasingly, more of them are coming from our own laboratories.

Speaker 1

Yeah. Thank you. Speaking of ZL-1503, I think it's a quite timely proof point of Zai Lab's R&D capabilities. Recently, we have quite encouraging first-in-human data. Rafael, how do you think, or what do you expect to see in the patient data next year to ultimately differentiate ZL-1503?

Rafael Amado
President and Head of Global Research and Development, Zai Lab

Yeah. ZL-1503, just to give a brief sort of synopsis of the molecule, it interdicts two chemokine signalings, if you will, IL-13, which mediates inflammation in T helper type two cells, and the paradigm of diseases is atopic dermatitis, and IL-31, which blocks in sensory nerve cells, pruritus or itching. That combination will help sort of interdict this inflammation, scratching, and worsening of inflammation and worsening of quality of life for the patients.

We have done healthy volunteer studies showing that the molecule is very potent in inhibiting phospho-STAT as well as downstream biomarkers, that it is safe, it does not have anti-drug antibodies, and the PK is actually long-lived because the molecule is engineered to have a long half-life of 40- 50 days. The study now is in the multiple ascending dose portion of the study, and we have two dose cohorts.

What we would like to see is obviously scores on the instruments that are used, such as EASI-75, EASI-90, and vIGA, which are scores that measure inflammation, that are at least commensurate with the drugs that are available today, like Dupixent or lebrikizumab, but also very quick abrogation of pruritus, which has an enormous impact on quality of life on these patients. Pruritus normally abrogates when inflammation goes away, so being able to have that improvement on days one or two, I think, would be a tremendous benefit in advance.

Speaker 1

Yeah. Thank you, Rafael. I will see if any questions from the audience. If no, maybe I will still keep asking my stupid questions. Yajing, as we already have these two excellent assets in hand, and I think we are capable of doing marketing them globally by ourselves, but maybe I think investors are still wondering, how would you deal with these assets going on forward? Will you keep the full global economics, or you were just bringing partners?

Yajing Chen
CFO, Zai Lab

Yeah. We have been getting these questions all the time. I think, to me, the answer is very simple. Our ultimate goal is to maximize the value for the patient and for our shareholders right now. I think that the internal capabilities are enhancing, right? So has our ability to really develop and commercialize it ourselves. That actually gave us the strategic flexibility what we wanted to do. Right now, as we speak, the base plan currently, we are going to develop and commercialize ourselves, zoci is the best first-in-class and best-in-class assets, and we have a team kind of fully capable of take it, move it forward. With that said, I think there are a lot of interest coming in, the inbounding interest.

So we are open for partnerships as long as the partnership can really bring additional value to patient, to our shareholders. To do that, I think an ideal partner to me is a partner that can accelerate the development, that can expand our commercial reach, and it can also bring complementary resources that can meaningfully increase the value of the program. If the partner comes with all that value, we are definitely open to it. If not, we are also in every confidence that we can do it ourselves.

Speaker 1

Yeah. Thank you, Yajing. If you are going to do it by yourself, what do you think, Zai Lab, how is Zai Lab prepared for going global?

Yajing Chen
CFO, Zai Lab

We are prepared. I think, from development side, we are already well on our way for our first BLA submission in 2027. The commercial launch for zoci, the plan is already well on the way, and we are definitely going to have commercial infrastructure and some of the capabilities starting build in 2027, be ready for launch in 2028.

Speaker 1

Yeah. Thank you. We still have time, so I want to ask Rafael. I think, if we look at the presentation material of Zai Lab, we still see there are plenty of early-stage pipeline. Would you please maybe spend a little more time about the following pipeline?

Rafael Amado
President and Head of Global Research and Development, Zai Lab

Yeah. Following zoci, I mentioned before that we are trying to innovate in antibody drug conjugates. We have one in the clinic, again, something called LRRC15, which is on malignant fibroblasts and also in tumor cells, and that's going through dose escalation now. It's focusing in sarcoma for now, but it will expand into other epithelial tumors. That's an example of one that came from our labs as well as it's sort of a hybrid business development internal. MUC17 will be a T-cell engager with some novel characteristics to try to minimize cytokine release syndrome, and that will be an IND before the end of the year.

Then in terms of immunocytokines, we have several of them. One that is a candidate that will be an IND in the first quarter is PD-1/IL-12. In immunology, we have other molecules bispecifics and interdict receptors and ligands, particularly around the IL-22 pathway, and those are coming from our internal laboratories. As you can see, it's sort of a blend of business development as well as internal capabilities, and at very different stages.

But we can utilize our speed and know-how, not just in China, but now globally, to move these molecules fast and be able to really capitalize if we see a signal of activity and the molecule is safe, and move it fast into the next stages of development. Our goal is to have approximately one IND every year, either coming from externally or internally from our labs. Yeah.

Speaker 1

Yeah. Thank you, Rafael. I see one question from the audience. Yes, please.

Speaker 4

For zoci, you used an outside ADC platform. As you develop other products or consider, are you looking at a different platform, same platform, or developing something internally? What would be the advantage?

Rafael Amado
President and Head of Global Research and Development, Zai Lab

Yeah. Often, we've partnered, like in the case of zoci, with MediLink. But for some of the molecules, we will make the antibody ourselves and then conjugate it with companies like MediLink. More and more, we're looking at other potential partnerships that give us the possibility of doing more innovation, like, for instance, dual payloads or biparatopic molecules, et c. We test in the laboratory conjugation with different systems, not just the TMALIN system from MediLink. You will see in the future that we will bring in payloads and linkers from other companies that have expertise in this field.

Speaker 1

Any other questions from the audience? If not, maybe to wrap up this session, I have a question. Maybe to imagine if we were sitting here in two years, and what do you think what need to have happened to truly validate that Zai Lab has already or truly transformed into a global innovation-led biopharm?

Yajing Chen
CFO, Zai Lab

Yeah. I'll be happy to be here again in two years to having this conversation. I think to me, it all comes down to the delivering, right, what we said. What I'm thinking right now, in two years, first of all, zoci will be already approved product in the U.S. market. That's very exciting. I also think that the zoci, beyond the approval, is already way on the way for the frontline development. Secondly, for ZL-1503, in two years, if we are here, we should already have patient data in atopic dermatitis, right? That program should be already way on the way for the later phase of development, and also in other indications as well. I would also like to see advancement of our other global pipeline by then as well.

On the regional business side, I expect the business to continue to grow and be increasingly profitable. I think the environment for the innovative product in China is improving. For VYVGART and KarXT, we see huge growth potential ahead of them, right, in two years. We also, at the same time, will be adding new assets to that regional portfolio. In two years, we're going to see a larger business and more profits coming out of that. I'm really hoping by then, Zai Lab is being viewed as a global pharmaceutical company, as we see ourselves, and that we are delivering what we said we would.